Cargando…

Use of fuzzy edge single-photon emission computed tomography analysis in definite Alzheimer's disease - a retrospective study

BACKGROUND: Definite Alzheimer's disease (AD) requires neuropathological confirmation. Single-photon emission computed tomography (SPECT) may enhance diagnostic accuracy, but due to restricted sensitivity and specificity, the role of SPECT is largely limited with regard to this purpose. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Rusina, Robert, Kukal, Jaromír, Bělíček, Tomáš, Buncová, Marie, Matěj, Radoslav
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939533/
https://www.ncbi.nlm.nih.gov/pubmed/20809946
http://dx.doi.org/10.1186/1471-2342-10-20
Descripción
Sumario:BACKGROUND: Definite Alzheimer's disease (AD) requires neuropathological confirmation. Single-photon emission computed tomography (SPECT) may enhance diagnostic accuracy, but due to restricted sensitivity and specificity, the role of SPECT is largely limited with regard to this purpose. METHODS: We propose a new method of SPECT data analysis. The method is based on a combination of parietal lobe selection (as regions-of-interest (ROI)), 3D fuzzy edge detection, and 3D watershed transformation. We applied the algorithm to three-dimensional SPECT images of human brains and compared the number of watershed regions inside the ROI between AD patients and controls. The Student's two-sample t-test was used for testing domain number equity in both groups. RESULTS: AD patients had a significantly reduced number of watershed regions compared to controls (p < 0.01). A sensitivity of 94.1% and specificity of 80% was obtained with a threshold value of 57.11 for the watershed domain number. The narrowing of the SPECT analysis to parietal regions leads to a substantial increase in both sensitivity and specificity. CONCLUSIONS: Our non-invasive, relatively low-cost, and easy method can contribute to a more precise diagnosis of AD.